Controversies in Drug Allergy: Drug Allergy Pathways.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30573422.
- Also identified by DOI 10.1016/j.jaip.2018.07.037 and PMC identifier 6466632.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Drug allergy pathways are standardized approaches for patients reporting prior drug allergies with the aim of quality improvement and promotion of antibiotic stewardship. At the International Drug Allergy Symposium during the 2018 American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress in Orlando, Florida, drug allergy pathways were discussed from international perspectives with a focus on beta-lactam allergy pathways and pragmatic approaches for acute care hospitals. In this expert consensus document, we review current pathways, and detail important considerations in devising, implementing, and evaluating beta-lactam allergy pathways for hospitalized patients. We describe the key patient and institutional factors that must be considered in risk stratification, the central feature of pathway design. We detail shared obstacles to widespread beta-lactam allergy pathway implementation and identify potential solutions to address these challenges.
Medical subject headings
- Anti-Bacterial Agents
- Consensus
- Drug Hypersensitivity
- Drug-Related Side Effects and Adverse Reactions
- beta-Lactams